Vertellus to buy Chemtrade businesses
Vertellus has signed a definitive agreement to acquire the potassium chloride, caustic pellets and vaccine adjuvant businesses of diversified US chemical firm Chemtrade. Terms were not disclosed. The transaction is expected to close during Q4, subject to regulatory approval and customary closing conditions.
The company, which is owned by Pritzker Private Capital, said that this will expand its capabilities “to manufacture and develop speciality ingredients in high-growth healthcare and pharmaceutical sectors”, notably medications for hypertension and diabetes, production of next-generation biologics and improving the effectiveness of certain vaccines.